GO
Loading...

Enter multiple symbols separated by commas

Stocks Amgen Inc

More

  • LinkedIn and Expedia are big market movers Friday, 31 Jul 2015 | 4:33 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:. LinkedIn Corp., down $23.89 to $203.26. Hanesbrands Inc., down $3.11 to $31.03.

  • July 31- The Dow and S&P 500 were dragged down on Friday by weak earnings from oil producers Exxon Mobil and Chevron, while the Nasdaq edged up after Amgen's profit beat expectations. Exxon Mobil shares fell 4 percent to $79.52 while Chevron was down 4.2 percent at $89.06 after quarterly profits slumped on falling oil prices. Amgen rose 4.7 percent to $179.64...

  • *Facebook, Whole Foods fall after results. *Expedia, Amgen jump in extended trade. Procter& Gamble, Facebook and Whole Foods Market all fell after quarterly reports that left investors wanting more.

  • July 30- Amgen Inc on Thursday reported higher-than-expected second-quarter profit and revenue, helped by strong sales of its Enbrel rheumatoid arthritis drug and cost cutting, and the company raised its full-year forecasts. Excluding special items, Amgen earned $2.57 per share, topping analysts' average expectations by 14 cents, according to Thomson...

  • Amgen tops Street 2Q forecasts Thursday, 30 Jul 2015 | 4:39 PM ET

    THOUSAND OAKS, Calif. _ Amgen Inc. on Thursday reported second-quarter profit of $1.65 billion. Amgen expects full-year earnings in the range of $9.55 to $9.80 per share, with revenue in the range of $21.1 billion to $21.4 billion. Amgen shares have risen roughly 8 percent since the beginning of the year, while the Standard& Poor's 500 index has risen slightly more...

  • TRENTON, N.J.— Amgen Inc. shares jumped in extended trading after the maker of osteoporosis drug Prolia easily beat Wall Street's second-quarter profit expectations and hiked its 2015 financial forecast. Amgen, based in Thousand Oaks, California, said Thursday it sees strong momentum for the second half of the year, with three new drugs launching, new approvals...

  • Nasdaq outperforms amid earnings, data Thursday, 30 Jul 2015 | 4:00 PM ET
    Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed narrowly mixed as investors digested more earnings and second-quarter GDP, a day after the Fed left interest rates unchanged.

  • Trades to go as FireEye, Amgen get ready to report Thursday, 30 Jul 2015 | 1:33 PM ET

    The "Halftime Report" traders give their plays on earnings for the second half of the day.

  • This biotech stock is about to break out: Trader Thursday, 30 Jul 2015 | 8:00 AM ET
    Amgen

    Technical analyst Todd Gordon looks at Amgen ahead of its earnings report. Explains why the stock could be poised to rally.

  • Earnings focus, but also seeking Fed clues in GDP Thursday, 30 Jul 2015 | 6:05 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Thursday brings another wave of earnings with companies from P&G to Amgen reporting, but markets will also be digging deep into GDP data for hints on the Fed.

  • Earnings focus, but also seeking Fed clues in GDP Wednesday, 29 Jul 2015 | 6:41 PM ET
    A trader works on the floor of the New York Stock Exchange.

    Thursday brings another wave of earnings with companies from P&G to Amgen reporting, but markets will also be digging deep into GDP data for hints on the Fed.

  • July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent, newly approved cholesterol drugs could "wreak financial havoc" among its clients. Express Scripts, which administers drug benefits for employers and health plans and also runs large mail-order pharmacies, has been challenging...

  • July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent new cholesterol drugs called PCSK9 inhibitors could "wreak financial havoc" among its clients. U.S. regulators on Friday approved the first of the new medicines, Praluent from Regeneron Pharmaceuticals Inc and Sanofi SA.

  • NEW YORK, July 27- Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger. As head of Actavis, he then sealed a $66 billion purchase of Botox-maker Allergan, beating out rival suitor Valeant...

  • Minefield for market with Fed, earnings, commodities Monday, 27 Jul 2015 | 8:08 AM ET
    An oil trader works on the floor of the New York Mercantile Exchange.

    The Fed meets next week, but a commodities meltdown and earnings season are adding to concerns about global growth and may steal some of its thunder.

  • New heart drugs come in more expensive than expected Monday, 27 Jul 2015 | 6:02 AM ET

    *Sanofi, Novartis set high prices for Praluent, Entresto. Praluent, made by Sanofi and Regeneron Pharmaceuticals, and Entresto from Novartis are both treatments that represent significant advances for millions of patients at risk of serious heart problems. Sanofi and Regeneron, which won U.S. approval on Friday for Praluent to treat stubbornly high...

  • TEL AVIV, July 26- After months of sparring in a hostile takeover bid for rival Mylan NV, Teva Pharmaceutical's move to buy Allergan Plc's generic drug business instead could be a smoother ride that will bring bigger returns, faster. Israel- based Teva, the world's largest generic drugmaker, is in advanced talks to buy Allergan's generic drugs unit for between $40-...

  • Battle coming for blockbuster cholesterol drugs Friday, 24 Jul 2015 | 3:59 PM ET
    A Sanofi lab worker packages vaccines.

    One large pharmacy benefit manager warns that costs from new PCSK9 drugs could reach as high as $150 billion annually.

  • WASHINGTON, July 24- The U.S. Food and Drug Administration approved a potent new cholesterol-lowering drug from Sanofi SA and Regeneron Pharmaceuticals Inc on Friday but limited its approved use to patients with a hereditary form of the condition and those with cardiovascular disease. The FDA ruling came just hours after European regulators recommended...

  • WASHINGTON— The Food and Drug Administration on Friday approved a first-of-a-kind drug that lowers artery-clogging cholesterol more than older drugs that have been prescribed for decades. The drug from Sanofi and Regeneron Pharmaceuticals Inc. offers an important new option for millions of patients at high risk of heart disease. But the drug's sky-high...